Sanofi-Aventis Offer To Buy Genzyme Seen As Starting Point For Long Negotiation
French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.
French pharma's initial offer in the $67 to $70 per share range expected to rise, perhaps into the $80s.